Albert Bourla has served as Chairman and Chief Executive Officer of Pfizer since January 2019, after more than two decades with the company in leadership roles across global commercial operations, vaccines, oncology, and R&D. He joined Pfizer in 1993 and later served as Group President of Pfizer Innovative Health, overseeing vaccines, oncology, rare disease, inflammation and immunology, and consumer healthcare, while shaping the company’s strategic pivot toward high‑growth therapeutic areas. Under his leadership, Pfizer has strengthened its focus on innovation-driven medicines and expanded global partnerships, enhanced operational efficiency, reinforcing its position as one of the leading biopharmaceutical companies.
A defining achievement of Bourla’s tenure was the rapid development, regulatory approval, and global distribution of the first COVID‑19 mRNA vaccine in partnership with BioNTech, delivering billions of doses worldwide and demonstrating the company’s capability for rapid scientific response. He has also expanded Pfizer’s oncology portfolio through strategic acquisitions and collaborations, advanced digital innovation in R&D and manufacturing, and implemented corporate restructuring to prioritize high-impact research.
The 100 CEOs featured here reflect the diversity and complexity of modern oncology leadership. In 2025, some lead the world’s largest cancer institutions; others guide specialized societies or emerging innovators. What unites them is responsibility: for millions of patients, for the integrity of science, and for the future direction of cancer care globally.
This list is not a celebration of power, but a recognition of stewardship, accountability, and impact – and of the leaders whose choices continue to shape the fight against cancer. For the many deserving individuals not mentioned in this list, we will continue to acknowledge, honor and elevate your voices in our daily publications from across the world.
See the full list of The 100 Most Influential CEOs in Oncology in 2025, and stay tuned for other special category nominations.
